571 related articles for article (PubMed ID: 29502288)
1. Immunotherapy for Head and Neck Squamous Cell Carcinoma.
Moskovitz J; Moy J; Ferris RL
Curr Oncol Rep; 2018 Mar; 20(2):22. PubMed ID: 29502288
[TBL] [Abstract][Full Text] [Related]
2. [Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress].
Huang LL; Shi YK
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):641-647. PubMed ID: 31550852
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
4. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
Miyauchi S; Kim SS; Pang J; Gold KA; Gutkind JS; Califano JA; Mell LK; Cohen EEW; Sharabi AB
Clin Cancer Res; 2019 Jul; 25(14):4211-4223. PubMed ID: 30814108
[TBL] [Abstract][Full Text] [Related]
5. An update on the immune landscape in lung and head and neck cancers.
Carlisle JW; Steuer CE; Owonikoko TK; Saba NF
CA Cancer J Clin; 2020 Nov; 70(6):505-517. PubMed ID: 32841388
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
7. The 5-Ws of immunotherapy in head and neck cancer.
Botticelli A; Mezi S; Pomati G; Cerbelli B; Di Rocco C; Amirhassankhani S; Sirgiovanni G; Occhipinti M; Napoli V; Emiliani A; Mazzuca F; Tomao S; Nuti M; Marchetti P
Crit Rev Oncol Hematol; 2020 Sep; 153():103041. PubMed ID: 32629362
[TBL] [Abstract][Full Text] [Related]
8. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.
Cavalieri S; Rivoltini L; Bergamini C; Locati LD; Licitra L; Bossi P
Cancer Treat Rev; 2018 Apr; 65():78-86. PubMed ID: 29574334
[TBL] [Abstract][Full Text] [Related]
9. Current studies of immunotherapy in head and neck cancer.
Dogan V; Rieckmann T; Münscher A; Busch CJ
Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma.
Mei Z; Huang J; Qiao B; Lam AK
Int J Oral Sci; 2020 May; 12(1):16. PubMed ID: 32461587
[TBL] [Abstract][Full Text] [Related]
11. Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy.
Rosenberg AJ; Perez CA; Guo W; de Oliveira Novaes JM; da Silva Reis KFO; McGarrah PW; Price KAR
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433330. PubMed ID: 38718318
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy.
Puntigam LK; Jeske SS; Götz M; Greiner J; Laban S; Theodoraki MN; Doescher J; Weissinger SE; Brunner C; Hoffmann TK; Schuler PJ
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707816
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Head and Neck Cancer.
Sim F; Leidner R; Bell RB
Hematol Oncol Clin North Am; 2019 Apr; 33(2):301-321. PubMed ID: 30833002
[TBL] [Abstract][Full Text] [Related]
14. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
Solomon B; Young RJ; Rischin D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
[TBL] [Abstract][Full Text] [Related]
15. Immune escape mechanisms in head and neck squamous cell carcinoma and implication for new immunotherapy approach.
Merlano MC; Denaro N; Garrone O
Curr Opin Oncol; 2020 May; 32(3):203-209. PubMed ID: 32195680
[TBL] [Abstract][Full Text] [Related]
16. [Clinical research on immune checkpoint and head and neck squamous cell carcinoma].
Yu D; Qi XM; Zhao X; Liu Y; Xue K; Jin CS; Wen LJ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Sep; 52(9):717-720. PubMed ID: 28910901
[TBL] [Abstract][Full Text] [Related]
17. The biology of combination immunotherapy in recurrent metastatic head and neck cancer.
Yuan X; Yi M; Zhang W; Xu L; Chu Q; Luo S; Wu K
Int J Biochem Cell Biol; 2021 Jul; 136():106002. PubMed ID: 33962022
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
Szturz P; Vermorken JB
BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
[TBL] [Abstract][Full Text] [Related]
19. [Head and neck cancer : promising results of immunotherapy].
Sivade A; Bensaid D; Monnier Y; Shabafrouz K; Bouchaab H; Cristina V
Rev Med Suisse; 2017 May; 13(563):1029-1031. PubMed ID: 28636292
[TBL] [Abstract][Full Text] [Related]
20. ["Immunotherapy in head and neck squamous cell carcinoma"].
Marret G; Borcoman É; Le Tourneau C
Rev Prat; 2021 Apr; 71(4):396-399. PubMed ID: 34161005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
